CLS enters the Italian market for Focal Laser Ablation together with the Nationwide Italian Company Tecnogamma s.r.l.
Lund, Sweden - Clinical Laserthermia Systems AB (publ) (CLS) today announced it has entered into an exclusive distribution agreement with Tecnogamma s.r.l. Company (Tecnogamma) to market and sell the CLS TRANBERG® product portfolio for urology in Italy.
The interest for focal therapies is growing in Italy and as previously reported the first cases using the CLS TRANBERG® Thermal Therapy System in prostate cancer patients were performed in April 2024 at University Hospital San Luigi Gonzaga in Turin by Prof. Francesco Porpiglia, Head of the Urological division. CLS is now entering into an exclusive distribution agreement with Tecnogamma s.r.l., a nationwide Italian company with long history and experience, especially in the field of urology, to market and sell the TRANBERG® product portfolio used for Focal Laser Ablation (FLA) of localized prostate cancer in Italy.
“The TRANBERG® product portfolio perfectly complements our current offering in urological oncology technologies.” said Luca Gulfi, MD of Tecnogamma. “Now we can offer a new, unique technology platform designed to treat localized prostate lesions in the most precise and accurate way to our large existing customer base, and to all new physicians.
CLS and Tecnogamma are now launching the TRANBERG® system with temperature control on the Italian market for use in Ultrasound-guided FLA of localized prostate cancer.
According to Perjan Pleunis, VP Sales Europe, this is an important first milestone in the Italian market for CLS. “Italy is a very important market for CLS. We’d like to show our commitment, not only to our new commercial partner, but also to some of the most influential specialist in the Italian market. I am looking forward to the collaboration with Tecnogamma, and I’m convinced that their competence and network will contribute to a successful introduction of the CLS TRANBERG® Thermal Therapy System in Italy.”
About localized prostate cancer
About 1.400.000 new cases per year of prostate cancer are reported worldwide with approximately 350.000 of them within EU. Although there are several prostate cancer treatment options, there is still an important unmet need for patients with localized prostate cancer who progress to the stage of intermediate risk. The currently available surgical options show significant risks and side effects related to urinary and erectile functions and quality of life.
For more information, please contact:
Dan J. Mogren, CEO, Clinical Laserthermia Systems AB (publ)
Tel: +46 – (0)705 – 90 11 40
E-mail: dan.mogren@clinicallaser.com
About Tecnogamma
With more than 35 years of experience providing new, emerging technologies for the Italian market in urological, neurosurgical and spine surgical field, Tecnogamma, based in Turin, is managing a network of expert dealers acting all over the country.”
For more information about Tecnogamma, please visit the Company's website Home – Tecnogamma.
About CLS
Clinical Laserthermia Systems AB (publ), develops and sells TRANBERG®|Thermal Therapy System and ClearPoint Prism Neuro Laser Therapy System with sterile disposables, for minimally invasive treatment of cancer tumors and drug-resistant epilepsy. The products are marketed and sold directly or through partners for image-guided laser ablation and are used in studies for treatment with imILT®, the company's interstitial laser thermotherapy for immune stimulating ablation with potential abscopal treatment effect. CLS is headquartered in Lund, Sweden, with subsidiaries in Germany, the United States and a marketing company in Singapore. CLS is listed on Nasdaq First North Growth Market under the symbol CLS B. Certified adviser (CA) is FNCA Sweden AB.
For more information about CLS, please visit the Company's website: www.clinicallaser.se